# Navigating ethical challenges in the FORTEe randomised controlled trial: a multi-centre staff survey on exercise intervention for children and adolescents undergoing cancer treatment

**Authors:** Francesca Alt, Elias Dreismickenbecker, Francesca Lanfranconi, Adriana Balduzzi, Eila Watson, Hayley Marriott, Joachim Wiskemann, Nikolai Bauer, Rodolf Mongondry, Martin Kaj Fridh, Alejandro Lucia, Carmen Fiuza-Luces, Ronja Beller, Filippo Spreafico, Barbara Konda, Milica Stefanović, Heidi Diel, Mareike Kühn, Lena Wypyrsczyk, Norbert W. Paul, Marie A. Neu, Jörg Faber

PMC · DOI: 10.1186/s12910-026-01414-6 · BMC Medical Ethics · 2026-02-25

## TL;DR

This study examines ethical challenges faced by healthcare professionals in a trial offering exercise to children with cancer, highlighting issues like participant burden and child autonomy.

## Contribution

The paper provides novel insights into ethical tensions in pediatric cancer research through a multi-center survey of healthcare professionals' experiences.

## Key findings

- Most healthcare professionals believed the trial's burden-benefit balance was appropriate.
- Moral distress was reported by nearly 70% of professionals dealing with prognosis-related events.
- Divergent views on children's decision-making capacity suggest a need for clearer guidance on pediatric autonomy.

## Abstract

The FORTEe randomised controlled trial (NCT05289739) investigates an exercise intervention for children and adolescents undergoing cancer treatment. Conducting research with this vulnerable population poses unique ethical challenges, including participant burden, child autonomy, and parental decision-making. This study explored the ethical experiences of healthcare professionals (HCPs) involved in the trial.

A multicentre survey was conducted across ten clinical sites in Europe using a structured, browser-based questionnaire comprising both closed and open-ended questions. Domains included burden and benefits assessment, informed consent, child autonomy, parental influence and moral distress. Quantitative responses were analysed descriptively, while qualitative data underwent content analysis.

Seventy-nine HCPs participated, including exercise professionals (n = 30), physicians (n = 19), nurses (n = 8), psychologists (n = 5), social workers (n = 3), one social scientist, one medical ethicist and 12 individuals in other roles. A large majority of respondents (86.1%) agreed or strongly agreed that the overall burden-benefit balance of trial participation was appropriate, while 11.4% were unsure and 2.5% disagreed. Open-text responses described perceived challenges related to questionnaire burden, logistical demands, and emotional discomfort associated with control-group allocation. Informed consent procedures were generally perceived as appropriate. However, some respondents reported situations in which parental influence appeared to outweigh children’s expressed preferences, and difficulties were noted in assessing children’s evolving decision-making capacity. Among HCPs who described prognosis-related events (n = 45), 68.9% described experiences they associated with moral distress, particularly in relation to communication and decisions regarding continuation of participation.

The trial's ethical climate was largely perceived as positive, though emotional and logistical burdens were noted. Reports of emotional discomfort and moral distress among staff highlight the ethical tensions between research integrity and individual well-being. Furthermore, divergent views on children’s capacity to give consent suggest the need for clearer guidance on paediatric autonomy and shared decision-making.

Ethically sound paediatric research must address real-world burdens and emotional dynamics beyond procedural compliance. Findings from the FORTEe trial staff survey highlight the importance of flexible, child-centred approaches, sustainable access to beneficial interventions, and institutional structures that promote ethical reflection.

Registered on ClinicalTrials.gov (NCT05289739, 21 March 2022) and in the German Clinical Trials Register (DRKS00027978, 28 January 2022).

The online version contains supplementary material available at 10.1186/s12910-026-01414-6.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** fatigue (MESH:D005221), Moral distress (MESH:D013313), distress (MESH:D012128), death (MESH:D003643), cardiopulmonary dysfunction (MESH:D006323), cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955331/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955331/full.md

---
Source: https://tomesphere.com/paper/PMC12955331